Evaluation of patients on sertindole treatment after failure of other antipsychotics: a retrospective analysis

Evaluation of patients on sertindole treatment after failure of other antipsychotics: a retrospective analysis

2008 BMC Psychiatry

Azorin, J. M. | Murteira, S. | Hansen, K. | Toumi, M. | Volume: 8, Issue: , Pages: 16, Adult, Antipsychotic Agents/adverse effects/*therapeutic use, Cross-Over Studies, Europe, Female, Hospitalization, Humans, Imidazoles/adverse effects/*therapeutic use, Indoles/adverse effects/*therapeutic use, Male, Middle Aged, Psychiatric Status Rating Scales, Psychotic Disorders/diagnosis/*drug therapy/psychology, Retreatment, Retrospective Studies, Schizophrenia/diagnosis/*drug therapy, Schizophrenic Psychology, Self-Injurious Behavior/prevention & control/psychology, Socioeconomic Factors, Suicide, Attempted/prevention & control/psychology, Treatment Failure, Treatment Outcome,

BACKGROUND: Use of the atypical antipsychotic sertindole was suspended for four years due to safety concerns. During the suspension, the regulatory authorities required further studies, including this one, to be conducted. The purpose of this study was to determine if a subset of patients with psychotic illness exists which particularly benefits from sertindole treatment after failure of other antipsychotic drugs, including atypical antipsychotics. METHODS: This was a retrospective single-arm observational crossover study of 344 patients, who served as their own controls. Patients mainly from the Sertindole Safety Study who had shown good response to sertindole, and who had followed up to four alternating six month periods of treatment with sertindole and other antipsychotics, were included. (In Period 1 patients took non-sertindole treatment, in Period 2, sertindole was taken, in Period 3, patients reverted to non-sertindole treatment, and in Period 4, sertindole was taken again.) Patient records for each period of treatment were assessed for objective data: number and duration of hospitalizations due to worsening of psychotic symptoms; the amount of self-harming behaviour; indicators of social status. Retrospective evaluation of changes in clinical symptoms from the patients’ records was also conducted. Dates and reasons for stopping and/or switching medication were also recorded. RESULTS: There was improvement in all objective measured parameters during the periods of sertindole treatment. In particular, the average number of hospitalizations per year due to worsening of psychotic symptoms was reduced in the following way in the group studied over four treatment periods: Period 1 (non-sertindole treatment) 3.4; Period 2 (sertindole treatment) 1.0; Period 3 (non-sertindole treatment) 2.0; Period 4 (sertindole treatment) 1.8. The duration of hospitalizations also decreased significantly during the periods of sertindole treatment. Results showed that patients improved in objective social parameters when switched to sertindole treatment; assessment of the patients’ affective lives showed a significant increase in the number of patients having a stable relationship during sertindole treatment; and assessment of the number of patients employed showed an increase after the first and second switch to sertindole treatment (from Period 1 to Period 2 and from Period 3 to Period 4, respectively). Adverse events and lack of efficacy were the main reasons for switching to sertindole. CONCLUSION: A group of patients benefited from sertindole after other antipsychotic treatments, including that with atypical antipsychotics, had failed. Further studies are needed to investigate if there is a specific patient profile that corresponds to these responders.

https://www.doi.org/10.1186/1471-244X-8-16